Browsing by Author Jang, JW

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 7 of 7
TitleAuthor(s)Issue DateViews
 
Ascending dose cohort study of inarigivir - A novel RIG I agonist in chronic HBV patients: Final results of the ACHIEVE trial
Proceeding/Conference:Journal of Hepatology
Yuen, RMFChen, CYLiu, CJJeng, RWJElkhashab, MCoffin, CKim, WGreenbloom, SRamji, ALim, YSKim, YJFung, SKim, DJJang, JWLee, KSAfdhal, NIyer, RMacfarlane, CJackson, KLocarnini, SChan, H
2019
2
 
Dose response and safety of the daily, oral RIG-I agonist Inarigivir (SB 9200) in treatment naïve patients with chronic hepatitis B: results from the 25mg and 50mg cohorts in the ACHIEVE trial
Proceeding/Conference:Journal of Hepatology
Yuen, RMFElkashab, MChen, CYCoffin, CFung, SGreenbloom, SJang, JWJeng, RWJKim, DJKim, YJKim, WLee, KSLim, YSRamji, AIyer, RMacfarlane, CJackson, KLocarnini, SAfdhal, NChan, H
2018
2
 
Hepatitis B virus (HBV) surface antigen (HBsAg) inhibition with isis 505358 in chronic hepatitis B (CHB) patients on stable nucleos(t)ide analogue (NA)-naïve CHB patients: phase 2a, randomized, double-blind, placebo-controlled study.
Proceeding/Conference:Journal of Hepatology
Yuen, RMFHeo, JJang, JWYoon, J-HKweon, YOPark, S-JBennett, FKwoh, J
2020
1
 
Impact of Alzheimer's Disease in Nine Asian Countries
Journal:Gerontology
Yang, YHMeguro, KKim, SYShim, YSYu, XChen, CLHWang, HLam, LSenanarong, VDominguez, JLu, PYLin, YTHu, CJChiu, PYFuh, JLWang, WFYu, BCLi, TWang, MWSitumeang, RFVJang, JWZhang, JChan, WCZhou, YYLou, HZhang, LYe, MChen, X
2016
29
 
Inarigivir demonstrates potent dose dependent anti-viral activity in HBV treatment-naive patients: role of HBeAg status and baseline HBsAg in anti-viral response
Proceeding/Conference:Hepatology
Yuen, RMFElkhashab, MChen, CYChen, YFCoffin, CSFung, SKGreenbloom, SJang, JWJeng, WJKim, DJKim, YJKim, WLee, KSLim, YSLiu, CJRamji, AIyer, RMacfarlane, CJackson, KLocarnini, SAfdhal, NHChan, HLYACHIEVE STUDY Investigators,
2018
7
 
Phase 2a, randomized, double-blind, placebo-controlled study of an antisense inhibitor (ISIS 505358) in treatment-naïve chronic hepatitis B (CHB) patients: safety and antiviral efficacy
Proceeding/Conference:Hepatology
Yuen, RMFHeo, JJang, JWYoon, JHKweon, YOPark, SJBennett, CFKwoh, TJ
2019
2
 
Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer
Journal:Oncogene
Lee, KSLee, YSLee, JMIto, KCinghu, SKim, JHJang, JWLi, YHGoh, YMChi, XZWee, HLee, HWHosoya, AChung, JHJang, JJKundu, JKSurh, YJKim, WJIto, YJung, HSBae, SC
2010
Showing results 1 to 7 of 7